Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + vinorelbine + cisplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents—paclitaxel, vinorelbine, and cisplatin—primarily used in the treatment of advanced non-small-cell lung cancer (NSCLC). Paclitaxel is a microtubule-stabilizing agent that promotes the assembly of microtubules and inhibits their disassembly during cell division. Vinorelbine is a semi-synthetic vinca alkaloid that acts as a mitotic spindle poison by inhibiting tubulin polymerization and preventing microtubule assembly. Cisplatin is a platinum-based compound that forms DNA crosslinks and induces apoptosis in rapidly dividing cells. The combination has shown synergistic activity with manageable toxicity profiles in clinical studies for metastatic NSCLC[1][3][4].
- Other names
- paclitaxelvinorelbine tartratecis-diamminedichloroplatinum(II)
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + vinorelbine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + vinorelbine + cisplatin.